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OBJECTIVE: The ideal dosage of cross-sex hormones remains unknown. The aim of this study was to evaluate the
luteinizing hormone, follicle-stimulating hormone, testosterone, estradiol and prolactin levels after low-dose
estrogen therapy with or without cyproterone acetate in transgender women.
METHODS: The serum hormone and biochemical profiles of 51 transgender women were evaluated before
gonadectomy. Hormone therapy consisted of conjugated equine estrogen alone or combined with cyproterone
acetate. The daily dose of conjugated equine estrogen was 0.625 mg in 41 subjects and 1.25 mg in 10 subjects,
and the daily dose of cyproterone acetate was 50 mg in 42 subjects and 100 mg in one subject.
RESULTS: Estrogen-only therapy reduced the testosterone, luteinizing hormone and follicle-stimulating hormone
levels from 731.5 to 18 ng/dL, 6.3 to 1.1 U/L and 9.6 to 1.5 U/L, respectively. Estrogen plus cyproterone acetate
reduced the testosterone, luteinizing hormone and follicle-stimulating hormone levels from 750 to 21 ng/dL, 6.8 to
0.6 U/L and 10 to 1.0 U/L, respectively. The serum levels of luteinizing hormone, follicle-stimulating hormone,
testosterone, estradiol and prolactin in the patients treated with estrogen alone and estrogen plus cyproterone
acetate were not significantly different. The group receiving estrogen plus cyproterone acetate had significantly
higher levels of gamma-glutamyltransferase than the group receiving estrogen alone. No significant differences in
the other biochemical parameters were evident between the patients receiving estrogen alone and estrogen plus
cyproterone acetate.
CONCLUSION: In our sample of transgender women, lower estrogen doses than those usually prescribed for
these subjects were able to adjust the testosterone and estradiol levels to the physiological female range, thus
avoiding high estrogen doses and their multiple associated side effects.
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’ INTRODUCTION
Transgender women (TW) have a female gender identity
and desire to live as a member of the female community (1).
Cross-sex identification typically has an early onset and
causes chronic suffering. To alleviate the distress associated
with belonging to an undesired gender group, sex reassign-
ment hormone therapy is indicated andmust be preceded by a
thorough psychological evaluation to establish the diagnosis
of gender dysphoria (2).
The therapeutic process for TW includes three mainstays:
psychotherapy, hormone therapy and sex reassignment surgery
(3). During the process of changing from the male to the female
phenotype, TW require the administration of cross-sex hor-
mones to mitigate the phenotypic signs of the male biological
sex and to develop female characteristics. After hormone
therapy, expected physical changes include breast devel-
opment and the redistribution of body fat to a female
pattern, as well as a decrease in facial hair growth, body
hair growth, muscle mass, testicular volume and sponta-
neous erections (4).
The aim of hormone therapy in TW is to promote the
development of female phenotypic characteristics using the
lowest effective estrogen doses to maintain serum estradiol
(E2) and testosterone (T) levels within the normal range for
women in the follicular phase of the menstrual cycle (3,5).
The treatment regimen of TW usually consists of estrogen
combined with a compound that suppresses androgen actions,
such as spironolactone, finasteride, flutamide or cyproterone
acetate (CA) (3). Spironolactone has a synergistic effect with
estrogen on physical changes (6). Finasteride and flutamide
are rarely used; the efficacy of finasteride is limited, and
flutamide is associated with liver toxicity (7).
CA is the most commonly used antiandrogen drug in Europe
and South America. CA acts as a potent competitive antagonistDOI: 10.6061/clinics/2018/e86
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of the androgen receptor and has additional progestational
activity, inhibiting luteinizing hormone (LH) release (8).
Different estrogen compounds and routes of administra-
tion exist for cross-sex hormone treatment. The use of oral
ethinyl E2 in transsexuals is associated with an increased risk
of venous thromboembolism and death from cardiovascular
events (9,10). Transdermal preparations are the safest forms
of estrogen administration, but oral 17b-E2, conjugated equine
estrogens (CEEs) and E2 valerate are also safer options than
oral ethinyl E2 for use in cross-sex hormone treatment
(3,11-13). The recommended estrogenic doses for feminization
of TW, according to the Endocrine Society guidelines, are
usually three times higher than those used for hormone
replacement therapy in postmenopausal women and are
similar to those used in hypogonadal patients (3,14).
We retrospectively analyzed the effects of lower doses of
estrogen in TW on suppressing endogenous T and maintain-
ing the physiological levels of E2 within the normal range for
premenopausal women in the follicular phase.
’ MATERIALS AND METHODS
This retrospective register study was approved by the
Ethics Committee of the Hospital das Clínicas da Faculdade
de Medicina da Universidade de São Paulo (HCFMUSP),
and signed informed consent forms were obtained from all
patients.
All patients consulting in our Transsexual Unit with
biochemical and hormonal data before and 6 months after
therapy were invited to participate in this retrospective anal-
ysis, and of the 58 patients who were invited, 51 agreed to
participate. The patients had a confirmed diagnosis of trans-
sexualism/gender dysphoria based on the International
Classification of Diseases (ICD-10) and Diagnostic and Stati-
stical Manual of Mental Disorders (DSM-V) criteria and were
assessed by mental health professional experts in gender
dysphoria (15,16).
The mean age at the first evaluation was 38.3±7.4 years
(range 23-58 years). All patients had a normal male pheno-
type (46, XY chromosome karyotype), and none of them had
previously undergone an orchiectomy.
The hormonal profiles (LH, follicle-stimulating hormone
[FSH], T, E2 and prolactin [PRL] levels) and biochemical
analyses (glycemia, total cholesterol [TC], high-density lipopro-
tein [HDLc], low-density lipoprotein [LDLc], very low-density
lipoprotein [VLDLc], triglycerides [TG], aspartate trans-
aminase [AST], alanine transaminase [ALT] and gamma-
glutamyltransferase [GGT] levels) were evaluated at the
baseline condition, after the withdrawal of all hormone
therapy for at least 3 months, and after 6 months of super-
vised hormone therapy.
Cross-sex hormone therapy consisted of oral CEE alone
and oral CEE combined with CA in 8 and 43 patients,
respectively. The daily doses of estrogen were 0.625 mg
(41 subjects) or 1.25 mg (10 subjects), and the daily doses
of CA were 50 mg (42 subjects) and 100 mg (1 subject).
Hormone assays
The LH, FSH, T, E2 and PRL levels were measured with
immunofluorometric assays (AutoDELFIA, Wallac, Finland).
The intra- and inter-assay coefficients of variation varied
from 5% to 10%.
Biochemical analysis
The fasting glucose levels were determined with an
automatic enzymatic colorimetric method using hexokinase
(Cobas Integra; Roche, Basel, Switzerland). The TC, HDLc,
LDLc, VLDLc and TG levels were analyzed with an automatic
enzymatic colorimetric method (Cobas Mira; F. Hoffmann-La
Roche, Basel, Switzerland). AST, ALT and GGTwere measured
with an automated biochemistry analyzer (Roche, Mannheim,
Germany).
Statistical analysis
The nonparametric Wilcoxon test was used to compare the
hormone levels before and after treatment. The nonpara-
metric Mann-Whitney test was used to compare the different
treatments. For continuous variables with normal distribu-
tions, Student’s t-test was applied. A significance level of 5%
was adopted in this study. The software used was STATA
version 13.0 (StataCorp LP, College Station, Texas, USA).
’ RESULTS
Cross-sex hormone treatment with estrogen alone (n=8
patients) reduced the T levels from 731.5 to 18 ng/dL
(p=0.01). The LH and FSH levels were also reduced from 6.3
to 1.1 U/L (p=0.049) and 9.6 to 1.5 U/L (p=0.01), respectively
(Table 1). In this group of patients, four subjects received
0.625 mg CEE daily, and four received 1.25 mg CEE daily; no
Table 1 - Serum hormone levels of 51 transgender women before and after 6 months of low-dose estrogen therapy with or without
cyproterone acetate.
Baseline (no CSH) Six months (on CSH) p
value*
Estrogen alone Estrogen plus CA
Median











LH (U/L) 6.3 (3.0-10.6) 6.8 (3.4-26.5) 6.6 (3.0-26.5) 1.1 (0.1-7.7) 0.6 (0.1-2.5) 0.6 (0.1-7.7) o0.001
FSH (U/L) 9.6 (1.5-18.2) 10.0 (1.5-36.5) 10.0 (1.5-36.5) 1.5 (1.0-7.7) 1.0 (0.7-7.7) 1.0 (0.7-7.7) o0.001
Testosterone (ng/dL) 731.5 (495-935) 750.0 (228-1420) 750 (228-1420) 18.0 (11-21) 21.0 (11-72) 20 (11-72) o0.001
Estradiol (pg/mL) 45.3 (13.0-53.9) 36.0 (19.9-92.0) 36.6 (13.0-92.0) 38.2 (13.0-61.0) 34.0 (13.0-88.0) 36.0 (13.0-88.0) 0.649
Prolactin (ng/mL) 7.6 (3.9-17.9) 7.6 (3.9-17.9) 7.6 (3.9-17.9) 16.3 (3.4-48.9) 16.3 (8.0-48.9) 16.3 (3.4-48.9) 0.004
Normal value for premenopausal women at the follicular phase of the menstrual cycle: LH, 2.2-6.8 IU/L; FSH, 2.4-9.3 IU/L; Testosterone, o98 ng/dL;
Estradiol, 22-215 pg/mL; Prolactin, 2-15 ng/mL.
CA: cyproterone acetate; CSH: cross-sex hormone.
*Median baseline compared to the median at 6 months.
2
Low-dose estrogen therapy in TW
Cunha FS et al.
CLINICS 2018;73:e86
differences were evident between the hormone levels in these
patient subgroups (Table 2).
Estrogen plus CA therapy (n=43 patients) reduced the
T levels from 750 to 21 ng/dL (po0.001). The LH and FSH
levels were also reduced from 6.8 to 0.6 U/L (po0.001) and
10 to 1.0 U/L (po0.001), respectively (Table 1). Thirty-seven
subjects received 0.625 mg CEE daily, and 6 subjects received
1.25 mg daily; all subjects received 50 mg CA (42 subjects) or
100 mg CA (1 subject) daily. After comparing these two CEE
subgroups, we observed that both treatments were able to
suppress the T levels to within the normal female range
(22 vs 18.9 ng/dL, p=0.3) (Table 2).
The estrogen levels before and after cross-sex hormone
treatment were not significantly different (p=0.6) (Table 1).
In contrast, the PRL levels increased after low-dose cross-sex
hormone therapy (p=0.004) (Table 1), with statistical sig-
nificance only in the ’estrogen plus CA’ group (p=0.009; data
not shown). Although an increase in the PRL levels was
observed in some patients after hormone therapy, only four
individuals had PRL values higher than the normal range
(2-15 ng/mL). The values were 48.9, 36 and 36.7 ng/mL for
three patients receiving 0.625 mg CEE plus 50 mg CA daily
and 30 ng/mL for one patient receiving 0.625 mg CEE daily.
The serum levels of LH, FSH, T, E2 and PRL in the patients
treated with estrogen alone or estrogen plus CA for 6 months
were not significantly different (p40.05) (Table 3).
No significant differences were evident for the biochemical
levels of glycemia (86±6 vs 86±13, p=0.8), TC (170±37 vs
173±34, p=0.7), HDLc (49±10 vs 50±14, p=0.7), LDLc (107
±36 vs 106±32, p=0.9), VLDLc (20±14 vs 19±12, p=0.8), TG
(84±34 vs 87±39, p=0.7), AST (22±7 vs 20±6, p=0.4), ALT
(20±9 vs 19±9, p=0.9) and GGT (24±14 vs 26±13, p=0.6)
before vs after cross-sex hormone therapy, respectively.
The group receiving estrogen plus CA presented higher
levels of GGT than the group receiving estrogen alone (16±
7 vs 24±7, p=0.009). No significant differences were evi-
dent for glycemia (98±22 vs 83±7, p=0.1), TC (168±40 vs
161±17, p=0.7), HDLc (54±11 vs 53±13, p=0.3), LDLc (94±
36 vs 94±16, p=0.4), VLDLc (19±13 vs 14±5, p=0.9), TG
(96±64 vs 76±19, p=0.7), AST (23±8 vs 18±3, p=0.3) and
ALT (19±12 vs 19±11, p=0.9) in the ’estrogen-alone group’
vs the ’estrogen-plus-CA group’, respectively.
’ DISCUSSION
TW generally have a psychological need to increase
estrogen replacement doses to acquire a female phenotype
as soon as possible. A higher estrogen dose is associated with
an increased risk of venous thromboembolic disease, pul-
monary embolism, myocardial infarction, stroke, hormone-
related tumors and adverse liver effects (17). In addition to
these common side effects of high-dose estrogen therapy,
increases in PRL levels and even prolactinoma development
have been described in TW (18-24).
The ideal dosage of cross-sex hormones is still unknown
because randomized controlled trials in this specific trans-
gender population are not available. The multiple types of
estrogens, variability of their measurement and different
routes of administration make the standardization of thera-
peutic regimens difficult. Long-term follow-up studies of hor-
mone treatment in transsexuals and of hormone replacement
therapy in biological females are used to guide cross-sex
hormone therapy in TW (3).
The use of a synthetic estrogen, ethinyl E2, in a large cohort
of transsexuals has been associated with an increased risk of
cardiovascular and thromboembolic events. Interestingly, the
Table 3 - Serum hormone levels in transgender women after 6 months of conjugated equine estrogen therapy with or without
cyproterone acetate therapy.
CEE plus CA (n=43) CEE alone (n=8) p value
Median (variation) Median (variation)
LH (U/L) 0.6 (0.1-2.5) 1.1 (0.1-7.7) 0.313
FSH (U/L) 1.0 (0.7-7.0) 1.5 (1.0-7.7) 0.594
Testosterone (ng/dL) 21.0 (11-72) 18.0 (11-21) 0.217
Estradiol (pg/mL) 34.0 (13.0-88.0) 38.2 (13.0-61.0) 0.835
Prolactin (ng/mL) 15.5 (8.0-48.9) 5.8 (3.1-36.7) 0.126
Normal value for premenopausal women at the follicular phase of the menstrual cycle: LH, 2.2-6.8 IU/L; FSH, 2.4-9.3 IU/L; Testosterone, o98 ng/dL; 17b-
estradiol, 22-215 pg/mL; Prolactin, 2-15 ng/mL.
CEE: conjugated equine estrogen; CA: cyproterone acetate.
Table 2 - Serum hormone levels after 6 months of treatment with different doses of conjugated equine estrogen alone or with





p value* 0.625 mg CEE plus
50 mg VA (n=37)**
1.25 mg CEE plus
50 mg CA (n=6)**
p value**
Median (variation) Median (variation) Median (variation) Median (variation)
LH (U/L) 1.1 (0.6-6.9) 0.8 (0.1-7.7) 0.561 0.6 (0.1-2.5) 0.7 (0.1-0.9) 0.619
FSH (U/L) 1.9 (1.0-7.7) 1.5 (0.1-2.1) 0.539 1.0 (0.7-7.7) 1.0 (1.0-3.3) 0.732
Testosterone (ng/dL) 15.5 (11-20) 19.5 (16-21) 0.191 22.0 (11-72) 18.9 (11-28) 0.292
Estradiol (pg/mL) 38.2 (13.0-45.1) 39.3 (13.0-61.0) 0.633 34.0 (13.0-88.0) 33.3 (18.0-68.0) 0.874
Prolactin (ng/mL) 5.2 (3.1-7.3) 12.0 (3.4-36.7) 0.355 15.5 (8.0-48.9) 14.7 (12.8-19.1) 0.874
Normal value for premenopausal women at the follicular phase of the menstrual cycle: LH, 2.2-6.8 IU/L; FSH, 2.4-9.3 IU/L; Testosterone, o98 ng/dL; 17b-
estradiol, 22-215 pg/mL; Prolactin, 2-15 ng/mL.
CEE: conjugated equine estrogen; CA: cyproterone acetate.
* 0.625 mg CEE compared to 1.25 mg CEE.
** 0.625 mg CEE plus 50 mg CA compared to 1.25 mg CEE plus 50 mg CA.
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vast majority of these adverse events occur during the first
year of estrogen treatment, and the risk is higher in patients
older than 40 years (9,10). Natural estrogens are safer options
than synthetic estrogens for cross-sex hormone treatment
(11-13). Transdermal preparation is the safest form of estro-
gen administration, especially in transsexual patients who
smoke or have diabetes because the transdermal prepara-
tion does not influence protein, lipoprotein or triglyceride
synthesis, thereby reducing the thrombotic and cardiovas-
cular risks (3).
In our hospital, transsexual patients are treated by a
multidisciplinary group and receive psychological support
before and after surgery. The psychological support controls
the anxiety of the patients as they develop the female
phenotype and allows us to treat our patients with the lowest
estrogen doses necessary to normalize androgen and estro-
gen levels.
This study is the first to evaluate the use of low doses of
estrogens in TW. We have demonstrated that low estrogen
doses alone or with CA are effective toward maintaining
androgen suppression and serum E2 within the normal
follicular-phase range.
Evaluations of the effects of low-dose estrogen therapy on
physical changes, namely, breast development, facial hair
growth, body hair growth and body fat redistribution, were
not possible in our patient population because all of the
patients reported prior use of other estrogen formulations
without medical supervision for a variable period of time.
However, the maintenance of estrogen levels in the normal
female range suggests that low-dose estrogen therapy may
be able to promote the satisfactory feminization of these
patients. The facial hair response to hormonal treatment in
transsexuals, even at high estrogen doses, is very poor and
often requires complementary cosmetic treatments such as
laser treatments and electrolysis. In addition, many signs of
feminization, including breast development, depend on not
only the estrogen dose but also the individual patient’s
sensitivity to estrogen. In a cohort of transsexuals receiving
high doses of estrogen, the result of breast augmentation
from hormones was described as modest, and the rate of
breast augmentation surgery in a series of transsexuals was
generally as high as 70% (25-27). Nevertheless, all patients in
our cohort achieved an advanced Tanner’ stage (IV and V) in
breast development.
The use of CA is especially important to alleviate andro-
genic signs and symptoms such as the male pattern of facial
and body hair and the undesired spontaneous penile erec-
tions frequently reported by TW. In our analysis, we noted
that CA was not critical for achieving androgen suppression
and that estrogen alone, even at low doses, was effective
toward suppressing the hypothalamic-pituitary-testicular
axis (8,28). Even so, we observed that the regimen compris-
ing estrogen plus CA achieved a more potent suppression of
LH levels than the regimen containing estrogen alone (from
6.8 to 0.6 IU/L, po0.001 vs from 6.3 to 1.1 IU/L, p=0.049,
respectively).
In our clinical practice, we avoid daily doses higher than
50 mg of CA because of its potential metabolic side effects,
including weight gain and high blood pressure. Moreover,
ethinyl E2 plus CA might induce a degree of insulin resi-
stance in TW (29). We observed that the GGT levels were
higher in the group receiving estrogen plus CA than in the
group receiving estrogen alone, although the both groups
presented with GGT levels in the normal range.
In our cohort, the estrogen levels before and after cross-sex
hormone treatment were not significantly different. The
conversion of male levels of T to estrogen before treatment
was similar to that achieved by the low-dose estrogen
treatment (30).
Estrogen-induced increases in PRL levels in many physio-
logical conditions, such as pregnancy and puberty, are well
known, and a mild increase in PRL levels in TW has been
described after estrogen therapy (31). Similarly, higher PRL
levels were identified in our cohort after low doses of
estrogen therapy. Although these levels were not statistically
significant in the group that received estrogen alone,
a significant increase was observed in the group receiving
estrogen plus CA. Other authors have reported increased
PRL levels associated with CA (32-34).
Our results demonstrated that the different doses of CEE
(0.625 vs 1.25 mg daily) were not significant in terms of the
elevation in the PRL level, probably due to the low dose of
estrogen in both subgroups. Additionally, we observed that
the two different doses of CEE had similar effects on
hormone levels after 6 months of treatment. However, these
data should be regarded with caution because the number of
individuals in each subgroup is very small, thus reducing the
statistical power of the sample.
In conclusion, in our sample of TW, lower estrogen doses
than those usually prescribed for these subjects were able to
adjust the T and E2 levels to the physiological female range,
avoiding the risks of high estrogen doses. Both regimens,
namely, CEE alone or with CA, achieved the laboratory goals
in the treatment of TW.
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